Physician profile
Thomas W Rennard
NPI 1346236809
$1,839.69
in general payments reported to CMS, 2019-2025
31 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $130 · 2021: $250 · 2022: $421 · 2023: $328 · 2024: $283 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $396.13 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $167.42 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $153.88 | 2019-2022 | |
| Abbott Laboratories | $125.49 | 2019-2024 | Octrode |
| Amgen INC. | $110.80 | 2020-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $89.93 | 2021-2022 | |
| Abbvie INC. | $85.76 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $81.43 | 2021-2022 | |
| Dexcom, INC. | $68.39 | 2022-2023 | Dexcom G6 Transmitter |
| Nevro Corp. | $57.12 | 2023 | Senza |
| Pfizer INC. | $52.88 | 2023-2025 | |
| Amarin Pharma, INC. | $43.59 | 2020-2022 | |
| Novo Nordisk INC | $42.59 | 2019-2022 | |
| Si-Bone, INC. | $34.50 | 2024 | |
| Sumitomo Pharma America, INC. | $32.48 | 2023 | Gemtesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $26.77 | 2025 | Tymlos |
| Daiichi Sankyo INC. | $26.39 | 2023 | Injectafer |
| Esperion Therapeutics, INC. | $24.77 | 2021 | |
| Glaxosmithkline, LLC. | $23.95 | 2019-2021 | |
| Cequr Corporation | $23.01 | 2023 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $20.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.82 | 2023 | |
| Inari Medical, INC. | $17.69 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Phathom Pharmaceuticals, INC. | $16.55 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2019 | |
| Boston Scientific Corporation | $15.85 | 2021 | |
| Ibsa Pharma INC. | $15.78 | 2019 | |
| Eisai INC. | $14.90 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.59 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rennard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.